Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Arikayce in Cystic Fibrosis Patients with Chronic Pseudomonas Aeruginosa Infection
NCT00558844Phase 2Completed
- Sponsor
- Insmed Incorporated
- Start
- Jan 2008
- Primary completion
- Jun 2009
- Modality
- Small Molecules, Lipid-based Nanoparticles
- Countries
- 1
01
Overview
A Phase 2 trial of amikacin liposome inhalation suspension in cystic fibrosis (CF), sponsored by Insmed Incorporated. Started Jan 2008; status: completed.
02
Drugs
amikacin liposome inhalation suspension
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on NCT00558844.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00558844.